Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus FOVANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus FOVANE.
DORAL vs FOVANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by inhibiting reuptake of serotonin at the synaptic cleft.
15-30 mg orally at bedtime, maximum 60 mg/day.
Adults: 10 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing, steady-state achieved by day 3.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal: 60% unchanged; fecal: 30% (as metabolites); biliary: 10%.
Category C
Category C
Benzodiazepine
Benzodiazepine